Ontology highlight
ABSTRACT:
SUBMITTER: Peddi PF
PROVIDER: S-EPMC3860880 | biostudies-literature | 2013 Mar
REPOSITORIES: biostudies-literature
Peddi Parvin F PF Hurvitz Sara A SA
Future oncology (London, England) 20130301 3
Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate, comprised of a potent cytotoxic drug connected via a stable linker to the anti-HER2 antibody, trastuzumab, thereby primarily targeting chemotherapy delivery to cells overexpressing the HER2 receptor. A Phase II randomized trial of T-DM1 in the front-line metastatic breast cancer setting revealed promising activity and improved safety compared with standard chemotherapy plus trastuzumab. Subsequently, a Phase III trial in patients ...[more]